Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Lunai Bioworks Inc. (NASDAQ:LNAI), a pioneer in AI-powered drug discovery and biodefense, today announced the formal adoption of its new corporate identity, reflecting a sharpened strategic focus and a streamlined capital structure following a 10:1 reverse stock split.
The rebranding from Renovaro Inc. to Lunai Bioworks marks a pivotal evolution in the company's mission: to capture biological signals at scale, decode them using AI, and validate them quickly in model systems. The new identity underscores Lunai's dual commitment to therapeutic innovation and biodefense preparedness, positioning the company as a category leader at the intersection of artificial intelligence, healthcare, and global security.
Effective September 30, 2025, Lunai's common stock will trade under the new ticker symbol "LNAI" on the Nasdaq Capital Market. The reverse stock split reduces outstanding shares from approximately 231.8 million to 23.2 million, enhancing capital efficiency and aligning with Nasdaq's minimum bid price requirements.
"Our new identity reflects both who we are and where we're going," said Dr. Gabe Musso, Chief Scientific Officer of Lunai's wholly owned subsidiary, BioSymetrics Inc. ("BioSymetrics"). "We're building platforms that not only accelerate therapeutic discovery but also safeguard against emerging biological threats."
Recent milestones include:
Transformer Platform Launch: Lunai introduced a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines. This innovation enables safe compound discovery while mitigating dual-use risks in biodefense.
Parkinson's Biomarker Program: Through BioSymetrics, Lunai advanced a preclinical biomarker discovery initiative in Parkinson's Disease, leveraging phenogrouping and multimodal data to stratify patients and identify novel therapeutic targets.
Platform validation via a competitive NIH grant: BioSymetrics recently was successful in obtaining a multi-year STTR grant which will allows for platform expansion.
Capital Structure Optimization: The reverse stock split strengthens Lunai's financial profile, supports long-term growth, and facilitates strategic partnerships with pharma, biotech, and government agencies.
David Weinstein, CEO of Lunai Bioworks, commented:
"With our Augusta platform, Lunai Bioworks is advancing precision neurology through AI-integrated therapeutics and biomarker intelligence. This transformation reflects our commitment to restoring cognitive health and resilience at scale."
Lunai Bioworks remains committed to ethical innovation, translational science, and scalable collaboration. With a refined identity and robust platform, the company is poised to lead the next wave of AI-driven breakthroughs in medicine and biodefense.
About Lunai Bioworks, Inc.:
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not related strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: "may", "could", "would", "should", "expect", "intend", "plan", "anticipate", "believe", "approximately", "estimate", "predict", "project", "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Lunai Bioworks encourages you to review the risk factors that may affect its future performance in its filings with the Securities and Exchange Commission. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company's filings with the SEC which can be found on the SEC's website at www.sec.gov.
Investor Contact
David Weinstein
Chief Executive Officer
305-918-1980
http://www.lunaibioworks.com/
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire